Kenneth S. Mobeck, Chief Financial Officer at EDAP TMS SA (EDAP), bought 5,000 shares at $4.75 ($24K) on 2026-08-14, disclosed to the SEC on 2026-08-17.
EDAP CFO Kenneth S. Mobeck purchased 5,000 shares for $23,750 at $4.75, marking the largest purchase of his career and signaling confidence in the company's strategic pivot. This high-level endorsement comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
The stock is currently trading at $4.215, down 4.2% over the last 90 days and 5.28% below its 52-week high of $4.45, suggesting the market may be overlooking recent operational successes.
1) Q4 2025 Earnings Call on June 1, 2026, where management highlighted 39% revenue growth in core HIFU and record commercial performance for Focal One. 2) The company's 2026 FocalTherics Investor Day on June 1, 2026, which outlined a shift toward high-growth, pure-play robotic focal therapy.
The stock is currently trading 35.1% above its 52-week low of $3.12, indicating that the recent price decline may have already priced in some of the fundamental improvements seen in the Q1 and Q4 earnings calls.
Something here stands out, but not much.